IDStewardship

  • Home
  • Articles
  • LEARN ANTIBIOTICS
  • Study Guide
  • Resources
  • Q&A
  • #ASPchat
  • Contributors
  • About

A comparison of eravacycline (Xerava) versus tigecycline (Tygacil)

With the approval of eravacycline in mid-2018 many people are wondering how this new tetracycline class antibiotic is different than tigecycline. In this article an infectious diseases pharmacists provides a general comparison of eravacycline (Xerava) versus tigecycline (Tygacil). 



Authored By: Timothy P. Gauthier, Pharm.D., BCPS-AQ ID


[Last updated: 27 September 2018 ]

Eravacycline (Xerava) is the latest antibiotic to hit the U.S. market, gaining FDA approval in August of 2018 for complicated intra-abdominal infection (note, studies for urinary tract infection have not been favorable). Inevitably as people learn about this new drug, questions will arise about it’s role in therapy and how it compares to other drugs.

Tigecycline (Tygacil) is the last tetracycline drug to come to market prior to eravacycline. Tigecycline and eravacycline share a number of commonalities, so in turn, many people are likely wondering how the two drugs compare.

In this article I provide a general comparison of eravacycline versus tigecycline. It should be noted that this is not a comprehensive review of the literature and readers are referred to the below references for more detailed information. This is not meant to support clinical decision making, but rather provide a superficial overview of how the drugs compare.



To start off, here is a table comparing eravacycline versus tigecycline. Much of the data below provided on eravacycline was derived from the manufacturer’s package insert, as published data with this antibiotic is currently limited…

Table 1. Comparison of Eravacycline (Xerava) versus Tigecycline (Tygacil)

Eravacycline

Tigecycline

Brand name:

Xerava

Tygacil

Generic available:

No

Yes

Manufacturer:

Tetraphase

Pfizer

Drug class:

Flurocycline type tetracycline

Glycylcycline tetracycline

FDA approval:

August 2018

June 2005

FDA-indications:

cIAI

cIAI, cSSSI, CABP

Mechanism of action:

Inhibition of bacterial synthesis via the 30S ribosomal subunit

Inhibition of bacterial synthesis via the 30S ribosomal subunit

Type of killing:

Mostly bacteriostatic

Mostly bacteriostatic

Mechanism(s) of resistance:

Efflux pumps, target site modifications

Efflux pumps

Effected by beta-lactamases:

No

No

MRSA activity:

Yes

Yes

VRE activity:

Yes

Yes

E. coli activity:

Yes

Yes

Klebsiella activity:

Yes

Yes

Acinetobacter activity:

Yes

Yes

Pseudomonas activity:

No

No

Bacteroides activity:

Yes

Yes

Mycobacterium activity:

Unable to find data

Yes

Adult dosing:

1mg/kg BID

100mg x1, then 50mg BID

Renal adjust:

No

No

Hepatic adjust:

Child Pugh C

Child Pugh C

Primary elimination route:

Fecal

Biliary/ fecal

Urine excretion:

20% unchanged drug

22% unchanged drug

Available oral:

No

No

Available IV:

Yes

Yes

Infusion time:

60 minutes

30-60 minutes

FDA boxed warning:

None

Higher all-cause mortality than comparators

Avoid in age <8 years:

Yes

Yes

Other side effects:

Infusion site reactions, nausea / vomiting (less than tigecycline)

Hepatic effects, pancreatitis, nausea / vomiting

Can cause fetal harm:

Yes

Yes

Safe during lactation:

No

Unknown

Major drug-drug interactions:

Strong CYP3A inducers & inhibitors; warfarin

Warfarin, oral contraceptives

Cost:

Not yet available

$157-$188 per 50mg

Abbreviations: cIAI = complicated intra-abdominal infection, cSSSI = complicated skin and skin structure infection, CABP = community acquired bacterial pneumonia, MRSA = methicillin-resistant Staphylococcus aureus, VRE = vancomycin-resistant Enterococci

What are the important differences?

Reflecting on the above table, package insert data, and literature below, eravacycline and tigecycline appear to share much common ground.  As for the more notable differences between the two, the clinical relevance of these points are not entirely clear yet, but includes:

  • Less nausea and vomiting with eravacycline as compared to tigecycline
  • More potent activity against carbapenem-resistant Enterobacteriaceae with eravacycline as compared to tigecycline
  • Better serum levels with eravacycline as compared to tigecycline
  • Less drug-drug interactions with tigecycline as compared to eravacycline
  • More clinical experience with tigecycline as compared to eravacycline
  • Tigecycline carries an FDA boxed warning that eravacycline does not

There may be other important differences not listed.

When might eravacycline be used?

Looking to when eravacycline may be employed in clinical practice, it seems the most obvious scenario will be as a substitute for tigecycline when a patient with significant nausea/ vomiting issues requires therapy for an intra-abdominal infection due to a multi-drug resistant organism (and/or if multiple allergies are present).

In a recent blog post, Dr. Paul Sax suggested several instances when eravacycline may be considered in practice, which is available here.

Questions I am still pondering…

  • What is the chance that a tigecycline-resistant isolate will also be eravacycline-resistant?
  • How difficult will it be for clinicians to procure eravacycline sensitivity testing?
  • If a patient has a tigecycline allergy, what is the chance that they also will have an eravacycline allergy?
  • What role does eravacycline have for the treatment of Mycobacterium spp.?
  • What consequences may arise from long-term eravacycline use?
  • What is the role of eravacycline for infections beyond intra-abdominal infections?

Closing comments

An expanding antimicrobial armamentarium is a good thing for patients with complicated infectious diseases, but new antibiotics bring many questions. Hopefully in the coming years additional data will be made available to address some of the questions posed here and also to further clarify what we have learned about eravacycline thus far.



Recommended Readings & Resources

  • Eravacycline (Xerava) package insert
  • Tigecycline (Tygacil) package insert
  • Eravacycline Approved by FDA – How Might It Be Used Today, And In The Future [HIV & ID Observations 2018]
  • Eravacycline for the treatment of intra-abdominal infections [EOID 2014]
  • Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent [Drugs 2016]
  • Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms [AAC 2016]
  • Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial [JAMA SURG 2017]
  • Tigeycline Boxed Warning
  • Tigecycline: a critical safety review [EODS 2015]
  • Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs [IJID 2015]

Have something to add or want to see an adjustment? Contact us here and we will consider making a change.


RECOMMENDED TO YOU


 

Filed Under: Infectious Diseases & Antimicrobial Stewardship

LEARN ANTIBIOTICS

Paperback Book

STEWARD PINS

Subscribe

Sign up for the monthly newsletter!

We will never spam you. We want you to like us. By clicking the Subscribe button, you accept the Terms of Service and Privacy Policy.

Categories

  • COVID-19
  • Healthcare At Large
  • Infectious Diseases & Antimicrobial Stewardship
  • Pharmacy News
  • Reality Check
  • Residency & Training
  • Facebook
  • Google+
  • Instagram
  • LinkedIn
  • Pinterest
  • Tumblr
  • Twitter
  • YouTube

Recent Posts

  • Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
  • The Learn Antibiotics Book
  • 2022 IDstewardship Year End Review
  • Antibiotics For Pediatric Respiratory Tract Infections In The Era Of Amoxicillin Shortages
  • What Does It Mean To Precept Responsibly & What Is The Precept Responsibly Podcast?

COVID-19

Musical Chairs & The ABCs of SARS-CoV-2 Monoclonal Antibodies

Musical Chairs & The ABCs of SARS-CoV-2 Monoclonal Antibodies

A Comparison Of Paxlovid Versus Molnupiravir: The First Oral COVID Antivirals

A Comparison Of Paxlovid Versus Molnupiravir: The First Oral COVID Antivirals

Five Things For Pharmacists To Know About The Omicron Variant

Five Things For Pharmacists To Know About The Omicron Variant

Molnupiravir – The New COVID Antiviral Named After Thor’s Hammer

Molnupiravir – The New COVID Antiviral Named After Thor’s Hammer

Tags

antibiotic Antibiotics antimicrobial stewardship bcps beta-lactam cancer Chemotherapy Clinical Controversies clinical pharmacist clinical pharmacy community pharmacist Critical Care emergency medicine Emoji Game fellowship figure1 Hepatitis C hospital pharmacist hospital pharmacy Infectious Disease infectious diseases Lifestyle MRSA NAPLEX Natural Disaster oncology pharmacist one-on-one penicillin allergy PGY2 Pharmacy Famous pharmacy fellowship Pharmacy Job pharmacy practice pharmacy residency pharmacy school pharmacy student Pharmacy technician PK-PD Compass Predatory Journals Rapid Diagnostic Testing social media student pharmacist study table transplant Zika

Penicillin Allergy Assessment Certificate Program

Recent

  • Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
  • The Learn Antibiotics Book
  • 2022 IDstewardship Year End Review
  • Antibiotics For Pediatric Respiratory Tract Infections In The Era Of Amoxicillin Shortages
  • What Does It Mean To Precept Responsibly & What Is The Precept Responsibly Podcast?

Search

Copyright 2016-2020 By Charlie Rose, LLC © · IDStewardship.com · Copyright · Privacy Policy · Terms · Contact